详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

New horizons in Parkinson's disease in older populations

37| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital of Capital Medical University, Beijing 100053, China. [2]Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing 100053, China. [3]Key Laboratory for Neurodegenerative Disease of the Ministry of Education, Beijing Key Laboratory for Parkinson's Disease, Parkinson Disease Center of Beijing Institute for Brain Disorders, Beijing, China. [4]Clinical Center for Parkinson's Disease, Capital Medical University, Beijing, China. [5]Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.

出处：

DOI：

ISSN：

关键词： Parkinson’s disease(PD) Parkinsonism movement disorder older people older population Parkinson’s

摘要：

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. Ageing is considered to be the greatest risk factor for PD, with a complex interplay between genetics and the environment. With population ageing, the prevalence of PD is expected to escalate worldwide; thus, it is of utmost importance to reduce the burden of PD. To date, there are no therapies to cure the disease, and current treatment strategies focus on the management of symptoms. Older adults often have multiple chronic diseases and geriatric syndromes, which further complicates the management of PD. Healthcare systems and care models necessary to address the broad needs of older PD patients are largely unavailable. In this New Horizon article, we discuss various aspects of PD from an ageing perspective, including disease management. We highlight recent advancements in PD therapies and discuss new care models with the potential to improve patient's quality of life.© The Author(s) 2023. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 1 区

医学

小类 | 1 区老年医学

最新[2023]版：

大类 | 2 区

医学

小类 | 1 区老年医学

JCR分区：

出版当年[2021]版：

Q1 GERIATRICS & GERONTOLOGY

最新[2023]版：

Q1 GERIATRICS & GERONTOLOGY

影响因子： 6 最新[2023版] 8.3 最新五年平均 12.782 出版当年[2021版] 9.954 出版当年五年平均 10.668 出版前一年[2020版] 6.7 出版后一年[2022版]

第一作者：

第一作者机构： [1]National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital of Capital Medical University, Beijing 100053, China.

共同第一作者：

通讯作者：

通讯机构： [1]National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital of Capital Medical University, Beijing 100053, China. [2]Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing 100053, China. [3]Key Laboratory for Neurodegenerative Disease of the Ministry of Education, Beijing Key Laboratory for Parkinson's Disease, Parkinson Disease Center of Beijing Institute for Brain Disorders, Beijing, China. [4]Clinical Center for Parkinson's Disease, Capital Medical University, Beijing, China. [5]Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]6-羟多巴胺诱导帕金森病大鼠模型行为学评价方法的探讨 [2]Parkinson's disease and the risk of gastrointestinal cancers: a two-sample Mendelian randomization study [3]Efficacy of medication for overactive bladder symptoms in 70 patients with Parkinson's disease [4]Education Moderates the Association of Probable REM Sleep Behavior Disorder With Cognitive and Motor Impairments in Community-Dwelling Older People. [5]帕金森病轻度认知功能障碍的M RI研究进展 [6]Case Report: Progressive Asymmetric Parkinsonism Secondary to CADASIL Without Dementia. [7]Clinical Significance of REM Sleep Behavior Disorders and Other Non-motor Symptoms of Parkinsonism [8]Movement disorder society criteria for clinically established early Parkinson's disease [9]Intrinsic capacity and healthy ageing [10]Quality of Life and Motor Outcomes in Patients With Parkinson's Disease 12 Months After Deep Brain Stimulation in China